Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs

Arquivos Brasileiros de Cardiologia

Volumn 96, Issue 2, 2011, Pages

  Silva, Pâmela Souza ^a   Lacchini, Riccardo ^a   de Aguiar Gomes, Valéria ^a   Tanus Santos, José Eduardo ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiovascular diseases; Genetic; Nitric oxide; Pharmacogenetics; Polymorphism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG ABSORPTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; EXON; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HAPLOTYPE MAP; HOMOZYGOTE; HUMAN; HYPERTENSION; INDEL MUTATION; INTRON; MICROSATELLITE INSTABILITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79953296501     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2011000200017     Document Type: Article

References (74)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409 (6822): 860-921.
2. The International HapMap Project. Nature. 2003; 426 (6968): 789-796.
3. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003; 348 (6): 538-549.
4. Gurwitz D, McLeod HL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics. 2009; 10 (2): 157-159.
5. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296 (15): 1858-1866.
6. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329 (7456): 15-19.
7. Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics. 2008; 9 (11): 1573-1577.
8. Bader JS. Systems approaches for pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2008; 9 (3): 257-262.
9. Topol EJ, Frazer KA. The resequencing imperative. Nat Genet. 2007; 39 (4): 439-440.
10. Dorn GW 2nd, Cresci S. The mechanistic imperative for pharmacogenomics. Pharmacogenomics. 2008; 9 (7): 801-803.
11. Marsh S. Pharmacogenetics: global clinical markers. Pharmacogenomics. 2008; 9 (4): 371-373.
12. Lacchini R, Sabha M, Coeli FB, Favero F F, Yugar-Toledo J, Izidoro-Toledo TC, et al. T allele of -344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertens Res. 2009; 32 (2): 159-162.
13. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G, et al. eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics. 2008; 9 (10): 1467-1473.
14. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329 (27): 2002-2012.
15. Kiechle FL, Malinski T. Nitric oxide: biochemistry, pathophysiology, and detection. Am J Clin Pathol. 1993; 100 (5): 567-575.
16. Cooke J P, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997; 48: 489-509.
17. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol. 2006; 46: 235-276.
18. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001; 104 (2): 191-196.
19. Sandrim VC, Palei AC, Metzger I F, Gomes VA, Cavalli RC, Tanus-Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008; 52 (2): 402-407.
20. Gomes VA, Casella-Filho A, Chagas AC, Tanus-Santos JE. Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome. Nitric Oxide. 2008; 19 (4): 345-350.
21. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986; 320 (6061): 454-456.
22. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998; 95 (16): 9220-9225.
23. Mason R P, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich). 2006; 8 (12 Suppl 4): 40-52.
24. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45: 89-118.
25. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 2001; 21 (1): 3-5.
26. Sharma JN, Abbas SA. Effect of captopril in the presence of kinin B2 receptor antagonist on duration of survival after prolonged coronary artery ligation in hypertensive rats. Methods Find Exp Clin Pharmacol. 2006; 28 (4): 217-221.
27. Cargnoni A, Comini L, Bernocchi P, Bachetti T, Ceconi C, Curello S, et al. Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. Br J Pharmacol. 2001; 133 (1): 145-153.
28. Wiemer G, Linz W, Hatrik S, Scholkens BA, Malinski T. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension. 1997; 30 (5): 1183-1190.
29. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002; 39 (2 Pt 2): 634-638.
30. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001; 89 (8): 678-683.
31. Veeravalli KK, Akula A. Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. Pharmacol Res. 2004; 49 (1): 23-29.
32. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R. Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol. 2001; 33 (3): 395-403.
33. Thai H, Wollmuth J, Goldman S, Gaballa M. Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther. 2003; 307 (3): 1171-1178.
34. Mason R P, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003; 23 (12): 2155-2163.
35. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol. 1999; 34 (2): 173-181.
36. Zineh I. Pharmacogenetics of response to statins. Curr Atheroscler Rep. 2007; 9 (3): 187-194.
37. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 (23 Suppl 1): III27-III32.
38. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003; 23 (5): 729-736.
39. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97 (12): 1129-1135.
40. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 2001; 155 (2): 347-357.
41. Jackson G. Treatment of erectile dysfunction in patients with cardiovascular disease: guide to drug selection. Drugs. 2004; 64 (14): 1533-1545.
42. Bivalacqua TJ, Usta M F, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res. 2004; 16 (1): 21-29.
43. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther. 2008; 326 (2): 380-387.
44. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001; 15 (10): 1718-1726.
45. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993; 268 (23): 17478-17488.
46. Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, et al. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem. 1994; 223 (3): 719-726.
47. Cooke GE, Doshi A, Binkley P F. Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. Pharmacogenomics. 2007; 8 (12): 1723-1734.
48. Pereira TV, Rudnicki M, Cheung BM, Baum L, Yamada Y, Oliveira PS, et al. Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias. J Hypertens. 2007; 25 (9): 1763-1774.
49. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod. 2009; 15 (2): 115-120.
50. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K, et al. T(-786)--> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol. 2000; 86 (6): 628-634.
51. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-->C mutation associated with coronary spastic angina. Hum Mol Genet. 2000; 9 (18): 2629-2637.
52. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation. 1999; 99 (22): 2864-2870.
53. Wang XL, Mahaney MC, Sim AS, Wang J, Wang J, Blangero J, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol. 1997; 17 (11): 3147-3153.
54. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun. 1998; 245 (1): 190-193.
55. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Chen L, et al. Effect of 27nt small RNA on endothelial nitric-oxide synthase expression. Mol Biol Cell. 2008; 19 (9): 3997-4005.
56. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Zhang Y, et al. Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene. J Biol Chem. 2008; 283 (21): 14685-14693.
57. Casas J P, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation. 2004; 109 (11): 1359-1365.
58. Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics. 2002; 12 (5): 407-413.
59. Godfrey V, Chan SL, Cassidy A, Butler R, Choy A, Fardon T, et al. The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev. 2007; 25 (3): 280-288.
60. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. Faseb J. 2007; 21 (11): 2655-2663.
61. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med. 2005; 56:303-320.
62. Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno HJr, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens. 2006; 24 (12): 2393-2397.
63. Metzger I F, Sertorio J T, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med. 2007; 43 (6): 987-992.
64. Metzger I F, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics. 2005; 15 (8): 565-570.
65. Abe K, Nakayama M, Yoshimura M, Nakamura S, Ito T, Yamamuro M, et al. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T>C polymorphism. Pharmacogenet Genomics. 2005; 15 (5): 329-336.
66. Nagassaki S, Sertorio JT, Metzger IF, Bem A F, Rocha JB, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med. 2006; 41 (7): 1044-1049.
67. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach R F, Rego EM, Tanus-Santos J.E. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis. 2007; 193 (2): 438-444.
68. Nagassaki S, Herculano RD, Graeff C F, Tanus-Santos JE. eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol. 2009; 65 (4): 385-392.
69. Kunnas TA, Lehtimaki T, Laaksonen R, Ilveskoski E, Janatuinen T, Vesalainen R, et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med. 2002; 80 (12): 802-807.
70. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003; 16 (10): 834-839.
71. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics. 2003; 13 (1): 7-17.
72. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289 (19): 2560-2572.
73. Jachymova M, Horky K, Bultas J, Kozich V, Jindra A, Peleska J, et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun. 2001; 284 (2): 426-430.
74. Eisenhardt A, Sperling H, Hauck E, Porst H, Stief C, Rubben H, et al. ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. Urology. 2003; 62 (1): 152-157.